Over the past few decades, substantial progress has been made in the diagnosis and treatment of breast cancer. Early identification of relapsed and metastatic disease has been a primary focus of ongoing research. Circulating tumor cells (CTCs) are implicated as harbingers of metastases. With advances in detection technologies, CTCs offer the option for real-time liquid biopsies. Methods to identify CTCs in the bloodstream by physical or biochemical properties, although feasible, still require improvements to promote widespread, reproducible use. Sufficient data support enumeration and assessment of changes in the number of CTCs as prognostic indicators, but controversy around their predictive utility for selecting treatments remains. As the technology to detect CTCs and characterize their heterogeneous molecular profile evolves, additional information will likely be obtained to guide targeted and individualized therapies. (JNCCN 2013;11:977-985) From Departments of
Analysis of Circulating Tumor Cells in Breast Cancer
Through coordinated scientific, medical, and public health advances, 5-year survival rates for breast cancer approach 90%. However, microscopic residual disease frequently results in local relapse or metastasis, leading to approximately 40,000 breast cancer deaths annually in the United States. 1 Circulatory spread of tumor cells was recognized in the 1800s. 2 These circulating tumor cells (CTCs) are thought to be a subpopulation detached from the primary or metastatic tumor sites, and reflect the heterogeneous characteristics of their source. Concentrations of these cells are estimated at as low as 1 CTC per billion normal blood cells. The ability to detect and evaluate the relevance of CTCs has greatly advanced since their initial identification, leading to ongoing exploration of their prognostic and predictive clinical applicability.
Identification of CTCs
Because of their usually low concentrations, identifying CTCs often requires enrichment. Technologies under assessment may rely on physical characteristics (size, cell density, electric properties, deformability), but more commonly, immunomagnetic separation and immunofluorescence/enzyme-linked immunosorbent assay-based assays are being applied. Detection through surface protein expression (the most common being EpCAM) and mRNA/reverse transcription polymerase chain reaction (RT-PCR) assays have also been studied. 3 In the setting of breast cancer, positive and negative biomarkers such as CD45, MUC-1, GA 73302, cytokeratins, and mammaglobin have been used for immunohistochemically based analysis. 4, 5 Studies of the different breast cancer cell subtypes (luminal, basal-like, normal-like, and HER2 + ) have shown variable EpCAM expression levels, and low/ lack of EpCAM expression in the normal-like subtype. 6 It is hypothesized that epithelial-to-mesenchymal transition (EMT), a process of cell dedifferentiation and loss of cell-cell contact and migration, during which cells lose their epithelial markers (EpCAM, E-cadherin) and take on mesenchymal markers, may be partly responsible for the heterogeneity among CTCs. 7 The only currently FDA-approved method for detecting CTCs is the CellSearch CTC Test (Veridex, Rarita, NJ), composed of an epithelial kit and cell spot-ter analyzer. From 7.5 mL of blood, anti-EpCAM antibodies are applied to immunomagnetically enrich and fluorescently label CTCs. Cytokeratin antibodies further distinguish between white blood cells, which express CD45, and carcinoma cells (markers including CK8, CK18, and CK19). Cells with phenotype CK8/18/19 + and CD45 -are counted as CTCs.
8 Nuclear staining uses 4′-6-Diamidino-2-phenylindole (DAPI). Limitations of this technology include the inability to recognize cells with low expression of EpCAM. Broadening the cytokeratin spectrum may improve detection of CTCs and reduce false-negatives. 9 The technology does allow for limited scope phenotypic estrogen receptor (ER) and HER2 analysis.
An alternative method is the AdnaTest BreastCancer Select system (AdnaGen, Langenhagen, Germany), which uses immunomagnetic beads coated with epithelial surface antigens (surface glycoprotein GA-773 2, HER2, or MUC-1). After detection of an antigen and isolation of mRNA with RT-PCR, the number of CTCs is indirectly determined. This test may allow for increased sensitivity over the CellSearch assay, with CTC detection rates ranging from 69% to 73%, 10,11 but it has not yet gained FDA approval. Testing a larger volume of blood with CellSearch can increase the yield of CTCs, but this is not practical, and when the criteria for defining a CTC is loosened, its association with survival seems to decrease.
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Additional and evolving CTC detection methods include microchip technology, leukapheresis, fluorescence-activated cell sorting, fluorescence cytometry, cell culture with identification of MUC-1 and CK-19, and laser scanning cytometry. 3, 13 Although microchip technology was originally described using silicon champers with EpCAM antibody-coated microposts, 14 newer assays are being developed that detect EpCAM-negative CTCs. 15 Ongoing studies are also evaluating circulating microRNAs in plasma to predict the presence of CTCs.
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Prognostic and Predictive Value of CTC Detection
Early-Stage Breast Cancer
Detection and enumeration of CTCs have not been translated into clinical utility primarily because of the lack of predictive value. The 2007 ASCO tumor marker guidelines stated that measurement of CTCs should not be used for diagnosis or treatment modifications. 17 Although the CellSearch system cutoff of 5 or greater CTCs per 7.5 mL of blood has been validated in metastatic breast cancer, isolation of a single cell (≥1 CTC per 7.5 mL of blood) has been considered the cutoff for CTC positivity in earlystage breast cancer. Differentiating between cells that play a role in spreading viable tumor deposits versus those which are biologically inert requires ongoing efforts. Numerous studies have been conducted of CTCs and survival in early-stage breast cancer (Table 1). [18] [19] [20] Two recent studies of patients with stage I-III breast cancer found that the presence of 1 or more CTCs per 7.5 mL of blood predicted shorter progression-free and overall survivals, and 1 or more CTC detected before initiating neoadjuvant chemotherapy adversely affected distant metastasis-free and overall survivals. 21, 22 In a meta-analysis of 49 studies enrolling 6825 patients in both early-stage and metastatic breast cancer settings, 23 
Metastatic Breast Cancer
CTCs have been found using the CellSearch CTC Test in approximately 60% of patients with metastatic breast cancer, [25] [26] [27] with higher numbers noted in those with multiple bone metastases. 28 In a retrospective analysis of 151 patients with metastatic breast cancer, baseline CTC levels of 5 or greater CTCs per 7.5 mL of blood using CellSearch were prognostic for decreased progression-free and overall survivals (from 29.3 to 13.5 months; Table 2 shows selected studies). 29 Another study of 74 patients also found a significant correlation between CTC levels and radiographic disease progression. 30 A nomogram based on number of CTCs at baseline and other characteristics has been developed to determine the probability of overall survival at 1, 2, and 5 years in patients with metastatic breast cancer starting firstline chemotherapy. 31 In a prospective study of 177 patients with metastatic breast cancer, CTC levels checked at any time during the course of treatment correctly predicted the clinical outcome. 25 Patients who converted from 5 or greater CTCs to fewer than 5 CTCs per 7.5 mL of blood experienced progression-free and overall survivals comparable to those of patients whose CTCs were never elevated. Of 177 patients, 138 underwent imaging studies at baseline and throughout treatment. The median overall survival of patients without radiologic progression and 5 or greater CTCs was significantly shorter than that of patients with radiologic progression and fewer than 5 CTCs (15.3 vs 26.9 months), whereas the median overall survival of patients with radiologic progression and fewer than 5 CTCs was significantly longer than patients with 5 or greater CTCs and radiologic progression (19.9 vs 6.4 months). 26 The prognostic value of CTCs was also compared with that of serum tumor markers in 267 patients with metastatic breast cancer treated with Detected in 42% at baseline CTC positivity was an independent prognostic factor for shorter PFS and OS Abbreviations: CTC, circulating tumor cell; OS, overall survival; PFS, progression-free survival.
first-line chemotherapy. 27 CTC counts of 5 or greater CTCs per 7.5 mL of blood at baseline were a strong prognostic factor for progression-free and overall survivals. Half of those patients had 5 or greater CTCs per 7.5 mL of blood at cycle 2, and changes were correlated with both progression-free and overall survivals, although neither tumor makers nor CTC changes between baseline and cycle 2 were associated with tumor response. At tumor progression, only CTC counts of 5 or greater per 7.5 mL of blood were prognostic for overall survival. 32 In the meta-analysis mentioned earlier, the prognostic value of CTCs in patients with metastatic breast cancer was significant for both progression-free survival (HR, 1.78) and overall survival (HR, 2.33). 23 CTCs detected before, during, and after systemic therapy all had comparable prognostic values. However, the effects of therapy on the prognostic value of CTCs could not be evaluated in the meta-analysis given the different treatment regimens used in the analyzed studies.
To further assess the utility of therapy decisions based on CTCs, SWOG designed a randomized phase III study on metastatic breast cancer patients using CellSearch, with results pending (ClinicalTrials.gov identifier: NCT00382018). Patients with 5 or greater CTCs after 1 cycle were randomized to either continue with current chemotherapy until progression or switch to a different regimen. Primary outcome measures include whether progression-free and overall survivals improve after changing to an alternative chemotherapy regimen based on CTCs, and the prognostic value of sequentially collected CTC values. Although the SWOG study is assessing first-line treatment, the ongoing phase III French CirCe01 study is focusing on the third and subsequent lines of treatment for patients with metastatic breast cancer, with the primary outcome of overall survival (ClinicalTrials.gov identifier: NCT01349842).
In HER2 + Breast Cancer
A study of patients with metastatic breast cancer using CellSearch and CTC-chip platforms found CTC counts to be lower in patients with HER2 + triplenegative breast cancer than in those with ER + breast cancer. 33 The investigators hypothesized that this may be from low EpCAM expression and a higher percentage of EMT-associated phenotype of tumors in the basal-like molecular subtypes. In a retrospective analysis of 517 patients with metastatic breast cancer, Giordano et al 34 + metastatic breast cancer in the study by Giordano et al 34 had received HER2-targeted treatments, the authors hypothesized that trastuzumab and lapatinib may have "removed" most circulating cells that overexpress HER2 from circulation, thus reducing the prognostic value of CTC enumeration. 34 Lack of prognostic value of CTCs in patients with metastatic breast cancer receiving HER2-targeted therapies was also seen in other studies. 36, 37 CTC detection did predict overall survival associated with HER2 + status in a study of 468 patients with metastatic breast cancer, but only in those who had not been treated with trastuzumab. 38 CTCs in response to trastuzumab and lapatinib were also analyzed in the neoadjuvant setting in the phase III Neo-ALTTO trial. 39 No significant correlation was seen between CTC detection at any point and pathologic complete response or FDG-PET/CT scan response.
As an adjunct to detecting HER2 overexpression in tumor biopsies, a different approach has been the evaluation of HER2 expression in the CTCs using immunohistochemistry or fluorescence in situ hybridization. Discordance in HER2 status between tumors biopsies and CTCs from the same patients was reported in several studies, with 23% to 39% of patients with HER2
-primary breast cancers found to have HER2 + CTCs. [40] [41] [42] The adjuvant phase III SUCCESS-B trial of early HER2 + breast cancer assessed baseline CTCs; patients were considered to have HER2 + CTCs if they had 1 or more detectable CTC with strong staining. 43 Results showed a discordance similar to that seen in other studies; of the 257 patients with HER2 + breast cancer with detectable CTCs, only 57.2% were determined to have HER2 + CTCs and 21.4% were questionable (having moderate HER2 staining). Data are pending on survival and the potential role of HER2 + CTCs in determining treatment efficacy. Another study assessed the prognostic value of HER2 + CTCs in patients with metastatic breast cancer starting a new line of treatment. 44 At first follow-up, patients with HER2 + CTCs (who may have had HER2
+ or HER2 -primary tumors) had significantly shorter progression-free and overall survivals than those without HER2 + CTCs. The utility of using anti-HER2 therapy in patients with HER2
-primary tumors and HER2 + CTCs was tested in a phase II study of patients with metastatic breast cancer given lapatinib. 45 Among the 7 of 96 patients who had HER2
+ CTCs who were eligible and treated with lapatinib, no objective tumor responses were seen. The premise of HER2-targeted therapy based on CTC expression alone is under investigation in the larger ongoing phase III DEFECT III trial, which is randomizing patients with initially HER2 -metastatic breast cancer and HER2 + CTCs to standard therapy with or without lapatinib (ClinicalTrials.gov identifier: NCT01619111).
Molecular Profiling of CTCs
Besides enumeration, substantial interest has been shown in molecular characterization of CTCs. Drugresistance profile has been explored through studying the expression of ATP-binding cassette transporters, which include multidrug resistance-related proteins (MRPs) that transport chemotherapeutics out of cancer cells. 46 Irrespective of tumor type and stage of disease, expression of MRPs on CTCs was observed to be predictive of resistance to chemotherapy in one trial. 46 Another study evaluated CTCs from 42 patients with metastatic breast cancer for the expression of MRPs and aldehyde dehydrogenase 1 (ALDH1, a marker of breast cancer stem cells). 47 Of the 19 patients with drug resistance CTC profiles, 15 had progressive disease, whereas all 9 with drug sensitivity profiles had stable disease or partial/complete responses. Patients whose CTCs expressed MRPs had a significantly shorter progression-free survival than those without (7.05 vs 16.44 months), suggesting that MRP overexpression on CTCs may predict poor response to specific chemotherapeutics. A significant correlation was also seen between MRPs expressed in CTCs and ALDH1, with this second marker more prevalent in HER2 + CTCs. Yet another trial of patients with metastatic breast cancer found that the percentage of ALDH1-high-expressing CTCs increased after chemotherapy, suggesting that CTCs that either possess or acquire stem cell features are more resistant to chemotherapy. 48 Studies have suggested that cancer stem cell (CSC)-like cells may evolve de novo from more differentiated cell types, and that CTCs may also undergo bidirectional interconversions between stem and nonstem compartments. 49 EMT has been proposed to be involved in the migration and dissemination of cancer cells. A prospective study of patients with HER2
+ metastatic breast cancer found that patients with EMT-inducing transcription factors in CTCs had more ALDH + CSC-like cells. 50 Whether EMTCTCs have prognostic value in patients with HER2 + metastatic breast cancer treated with HER2-targeted therapy is unknown. In one study, in a subset of 11 patients, an association was observed between the presence of mesenchymal CTCs and breast cancer progression, and between reversible shifts in EMT characteristics and response to therapy. Regulators of EMT including FOXC1 transcription factor and components of transforming growth factor (TGF) β pathways were expressed in mesenchymal CTCs. 51 CTCs with CSC-like features could also provide opportunities for novel targeting strategies, especially in patients with triple-negative breast cancer with or without BRCA mutations/silencing and with sensitivity to DNA damaging agents, such as platinum compounds. In these settings, testing for platinum-resistance markers may be useful. For example, the excision repair cross-complementation group 1 (ERCC1) enzyme removes cisplatin-induced DNA adducts. Low expression of ERCC1 on CTCs of patients with metastatic non-small cell lung cancer correlates with increased progression-free survival in those who received platinum chemotherapy. 52, 53 ERCC1 testing could also be pursued in breast cancers, because CTC-based selection of chemotherapy regimens could potentially be incorporated into treatment planning. 40 In addition, testing for drug resistance markers and CSC-like features and for expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, and members of downstream signal transduc-tion pathways such as PI3K and phospho-AKT expression has also been studied in CTCs of patients with early-stage and metastatic breast cancers. The molecular characteristics may vary between the primary tumors and CTCs. 54 A clonal mutation analysis on CTCs performed in a study of 40 patients with metastatic breast cancer detected mutations of PIK3CA, STK11, and NRAS, with plans to compare the mutational profile between CTCs and primary/ metastatic tumors. 55 While awaiting further development of targeting agents, the high prevalence and significance of the p53 mutation, especially in triple-negative breast cancer, presents a potential for therapeutic intervention. Accordingly, p53 mutations were identified via whole genome amplification through extracting DNA from single CTCs in a pilot trial, and the findings suggested variable mutations and a high prevalence in CTCs. 56 Attempts are ongoing to identify additional prognostic and potentially targetable markers. CTCs from patients with breast cancer using immunomagnetic enrichment reveal increased levels of gene expressions associated with metastasis, such as NPTN, S100A4, and S100A9, and those associated with EMT, such as VIM, TGFß1, ZEB2, and FOXC1. 57 A study of 130 patients with metastatic breast cancer before the start of first-line therapy evaluating mRNA gene expression levels in relation to timeto-treatment switch (TTS) found a 16-gene CTC profile that correlated with TTS or death within 9 months. 58 Analysis of CTC genome-wide copy number alterations over time has also been described. 59 Although genomic alterations were preserved in individual patients, new alterations in the course of disease progression were also seen, which may allow for evaluation of genomic events connected with a patient's breast cancer progression. Circulating tumor DNA levels are also under investigation, because they may be better correlated with tumor burden changes than CTCs. 60 
Conclusions
Enumeration of CTCs has been shown in numerous studies to have prognostic value for progression-free and overall survivals in both early-stage and metastatic breast cancers. However, the value of CTCs as predictive markers for treatment outcomes associated with either chemotherapy or targeted therapies is still not completely clear; ongoing clinical trials may provide more conclusive answers. Difficulty obtaining CTCs from peripheral blood, different techniques used for CTC enumeration, and analyses using EpCAM-only-based systems have provided additional challenges. Given further advances in molecular analysis of CTCs, these cells may become guiding targets for personalized therapeutic interventions, because they present or acquire differing genotypes and phenotypes compared with primary and metastatic tumors, and may provide additional real-time information on tumor biology and drug resistance. 
